Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling?

More than a simple climb, the drugmaker’s stock re-rated on a growth story that somehow keeps getting bigger.

Let’s be clear about what a 54% stock gain in nine months actually means for a company the size of Eli Lilly (LLY). It’s not a bounce. It’s a fundamental repricing. While the S&P 500 was putting up a respectable 15% return, LLY shareholders were in a different league entirely, watching the company add hundreds of billions in market value to become a firm worth over $1 trillion.

Wall Street skeptics have looked at this massive surge and called the stock’s valuation “irrational.” And on the surface, seeing a 148-year-old pharma giant price itself like a Silicon Valley tech darling does feel extreme.

But is it really irrational?

When a company the size of Lilly posts 56% year-over-year revenue growth and converts it at a staggering 47% operating margin, it’s not an anomaly. It’s a fundamental repricing. Here is why the market’s math might actually be right.

A Growth Rate From A Different Planet

In its most recent quarter, Lilly’s revenue grew 56% from the year before. That figure is startling on its own, but the context makes it even more potent. This isn’t a one-off jump. The company’s revenue growth over the last twelve months is 47.4%, a significant acceleration from its already impressive three-year average of 37.9%. You may wonder that a company this large is supposed to be getting slower, not faster. The engine here is its incretin franchise, with Mounjaro and Zepbound sales hitting a combined $12.8 billion in a single quarter.

This growth is also highly profitable. Lilly’s operating margin now sits at 47.3%, a huge leap from its 35.3% three-year average. The company is converting its historic sales boom directly into profit at a stunningly efficient clip.

The Next Wave Arrives

Was this nine-month surge simply a reward for past performance? Wall Street was also looking ahead, and Lilly kept giving it more to like. During this window, the company secured a landmark FDA approval for Foundayo, an oral weight-management pill. As CEO David Ricks noted, this was “the first time a new incretin medicine has been launched with obesity as its indication first.” It’s a massive new market opportunity, and Lilly is first in line with a convenient pill.

The company also went on a shopping spree, announcing agreements to acquire multiple clinical-stage biotechs like Orna Therapeutics and Centessa Pharmaceuticals to bolster its pipeline for the years ahead. The message was clear: the current gusher of cash would be used to build the next one.

But as the company rolls out new platforms like Lilly Employer Connect to get its drugs to patients, it also surfaces the one question that hangs over this entire story. The science is a triumph. The logistics are another matter.

Now that Lilly has proven it can invent world-changing drugs, can it invent a business model that gets them to everyone?

Where Does This Fit In Your Portfolio

Chasing single-name moves is its own kind of risk. The Trefis High Quality (HQ) Portfolio takes the other side of that bet: 30 quality names, sized and re-balanced with discipline, and a track record of outpacing the S&P 500, S&P Mid-cap, and Russell 2000 with cumulative returns of over 105%.